Results 41 to 50 of about 4,011 (178)

Treprostinil Reconstitutes Mitochondrial Organisation and Structure in Idiopathic Pulmonary Fibrosis Cells

, 2023
Idiopathic pulmonary fibrosis (IPF) presents as an incurable change in the lung tissue and mitochondrial dysfunction of unknown origin. Treprostinil, a prostacyclin analogue, has been suggested for IPF therapy.
Michael Roth, Antonio Molino, Wei-Chih Chen, Christopher Lambers, Peter Jaksch, Lei Fang, Alessandro Saglia   +6 more
core   +2 more sources

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients

Pulmonary Circulation, 2023
Continuous subcutaneous (SubQ) treprostinil is an effective therapy for pediatric patients diagnosed with pulmonary hypertension (PH). To date, the clinical characteristics and factors associated with failure to tolerate this therapy have not been ...
Julia McSweeney, Elizabeth Colglazier, Jasmine Becerra, Brienne Leary, Kathleen Miller‐Reed, Stephen Walker, Katy Tillman, Melissa Magness, Michelle Ogawa, Whitney Bannon, Tisha Kivett, Emma O. Jackson, Anne Davis, Cathy Shepard, Susan Richards, Elise Whalen, Shannon Engstrand, Zachary DiPasquale, Jean A. Connor   +18 more
doaj   +1 more source

Use of treprostinil in pediatric pulmonary hypertension

, 2020
International audienceAdd-on therapy with prostacyclin in pediatric refractory pulmonary hypertension poses a challenge, especially when considering continuous intravenous administration in younger children. A search for alternate routes of drug delivery
Werner, Oscar, Gavotto, Arthur, Thomas, Fanny, Amedro, Pascal, Arthur Gavotto, Fanny Thomas, Oscar Werner, Moreau, Johan, Johan Moreau, Pascal Amedro   +9 more
core   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Synthetic routes to treprostinil N-acyl methylsulfonamide

, 2020
The synthesis of the prodrug candidate, treprostinil N-acyl methylsulfonamide 5 was accomplished from treprostinil 2 utilising protecting group strategies.
Laing, Peter, Clapp, Lucie H., Picken, Christina; id_orcid, Brocchini, Steve, Shen, Lei   +4 more
core   +1 more source

IPF-Fibroblast Erk1/2 Activity Is Independent from microRNA Cluster 17-92 but Can Be Inhibited by Treprostinil through DUSP1

Cells, 2021
Idiopathic pulmonary fibrosis (IPF) is a progressive terminal lung disease, and therapies aim to block fibrosis. Fibroblast proliferation is controlled by C/EBP-β, microRNA cluster 17-92 (miR17-92), and Erk1/2 mitogen-activated protein kinase. This study
Sabrina Blumer, Lei Fang, Wei-Chih Chen, Petra Khan, Katrin Hostettler, Michael Tamm, Michael Roth, Christopher Lambers   +7 more
doaj   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

Clinical Pharmacology &Therapeutics, EarlyView.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus, Sheng‐Ya Wang, Edward W. G. Ashton, Rosie K. Barrows, Molly Monks, Yuzhang Ge, Arthur Lefebvre, Steven A. Niederer   +7 more
wiley   +1 more source

Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis

Pulmonary Circulation, 2018
There are limited data investigating the epidemiology and resource utilization associated with parenteral prostacyclin use in children. We sought to examine national trends in treatment practices and resource utilization during prostacyclin initiation ...
Stephen A. Hart, Gaurav Arora, Brian Feingold   +2 more
doaj   +1 more source

Effects of Single and Multiple Dose Tiotropium/Olodaterol in Chronic Obstructive Pulmonary Disease on Alveolar Gas Exchange Measured by Hyperpolarized 129Xe MRI

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Long‐acting muscarinic antagonists/long‐acting beta adrenoreceptor agonists lead to lung deflation and improved microvascular perfusion in hyperinflated chronic obstructive pulmonary disease (COPD), but with an unclear time course. Purpose To investigate the effect of inhalation of tiotropium/olodaterol (TIO/OLO) on MRI measures of ...
Agilo L. Kern, Thomas Kayser, Robin A. Müller, Andreas Voskrebenzev, Filip Klimeš, Frank Wacker, Jens M. Hohlfeld, Jens Vogel‐Claussen   +7 more
wiley   +1 more source